NZ297424A - Use of an aminopurine derivative to treat latent infection of the herpes virus - Google Patents

Abstract

A purine derivative of formula (A) or a bioprecursor or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative thereof is in the preparation of a medicament for the reduction or prevention of herpes virus infection becoming latent and subsequently reactivating in mammals wherein the administration of the medicament commences more than 18 hours post-infection. The preferred purine derivative is famciclovir and the infection is herpes simplex type 1 or 2.

Description

New Zealand No. 297424 International No. PCT/EP95/04692 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION Title of Invention: Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections Name, address and nationality of applicant(s) as in international application form: SMITHKLINE BEECHAM P.L.C., of New Horizons Court, Brentford, Middlesex TW8 9EP, United Kingdom 297 4 2 4 use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpes virus infections This invention relates to treatment of latent infection of herpesviruses. When used herein, 'treatment' includes prophylaxis as appropriate. 5 EP-A-141927 (Beecham Group p.l.c.) discloses penciclovir, the compound of formula (A): N < I n- O nh X n nh, hock (<^2)2 ,-CH -ch2-oh (A) and salts, phosphate esters and acyl derivatives thereof, as antiviral agents. The sodium salt hydrate of penciclovir is disclosed in EP-A-216459 (Beecham Group p.l.c.). Penciclovir and its antiviral activity is also disclosed in Abstract P.V11-5 p. 193 of 'Abstracts of 14th Int. Congress of Microbiology', Manchester, England 7-13 September 1986 (Boyd eL al.).

Orally active bioprecursors of the compound of formula (A) are of formula (B): OCT 1 (ch2)2 ho-ch2-ch-chz-oh (B) V 2 997 4^^ and salts and derivatives thereof as defined under formulaTX); wherein X is C j.g alkoxy, NH2 or hydrogen. The compounds of formula (B) wherein X is Ci_£ alkoxy or NH2 ^ disclosed in EP-A-141927 and the compounds of formula (B) wherein X is hydrogen, disclosed in EP-A-182024 (Beecham Group p.l.c.) are preferred 5 prodrugs. A particularly preferred example of a compound of formula (B) is that wherein X is hydrogen and wherein the two OH groups are in the form of the acetyl derivative, described in Example 2 of EP-A-182024, hereinafter referred to as famciclovir.

The compounds of formulae (A) and (B) and salts and derivatives thereof 10 have been described as useful in the treatment of infections caused by herpesviruses, such as herpes simplex type 1 and herpes simplex type 2.

Previous work has shown that if antiviral treatment is delayed beyond a few hours after infection then latency is established. Once a latent infection is established, the infection can recurr.

It has now been shown in mice that famciclovir treatment can prevent the establishment of competent latency when treatment is commenced 18 h (first experiment) and up to 4 days (second experiment) after infection. It has also now been shown that latency can be prevented in an experiment in immunocompromised mice. The potential clinical advantage is that a patient, within 4 days of contact, may 20 be treated with famciclovir to prevent not only the acute infection but also the development of latency and so avoid recurrences. Furthermore, it is thought that there may be a slow natural loss of latently infected cells and recurrent infections may be required in order to maintain the burden of latendy infected cells by establishing latency in new cells. Therefore, suppressive treatment with famciclovir over a 25 prolonged period (up to several years) may prevent new cells becoming latently infected. The result would then be curative treatment, the patient having no recurrences thereafter.

Accordingly, the present invention provides a method of treatment of latent infection of herpesviruses in mammals, including humans, which method comprises 30 the administration to the mammal in need of such treatment, an effective amount of a compdund of formula (A): INTELLECTUAL PROPFPhY OFPJCr] OF N.Z. ■ 2 9 OCT 1999 RECEIVED 0 N.

Ui NH NH, (CH2)2 HO-CH2 -CH -CHa-OH (A) or a bioprecursor, or a pharmaceuticaUy acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing.

The term 'acyl derivative1 is used herein to include any derivative of the compounds of formula (A) in which one or more acyl groups are present. Such derivatives are included as bioprecursors of the compounds of formula (A) in addition 10 to those derivatives which are per se biologically active.

The compound of formula (A) may be in one of the forms disclosed in EP-A-216459 (Beecham Group p.l.c.).

Examples of bioprecursors, pharmaceutical!y acceptable salts and derivatives are as described in the aforementioned European Patent references, the subject matter 15 of which are incorporated herein by reference.

A particular compound of formula (B) of interest is 9-(4-acetoxy-3-acetoxymethylbut-l-yl)-2-aminopurine, known as famciclovir (FCV), the well-absorbed oral form of penciclovir (PCV).

The compound of formula (A), bioprecursors, salts and derivatives may be 20 prepared as described in the aforementioned European Patent references.

The compound, in particular, famciclovir, may be administered by the oral route to humans and may be compounded in the form of syrup, tablets or capsule. When in the form of a tablet, any pharmaceutical carrier suitable for formulating such solid compositions may be used, for example magnesium stearate, starch, lactose, 25 glucose, rice, flour and chalk. The compound may also be in the form of an ingestible capsule, for example of gelatin, to contain the compound, or in the fonn of a syrup, a solution or a suspension. Suitable liquid pharmaceutical carriers include ethyl alcohol, glycerine, saline and water to which flavouring or colouring agents may be added to form syrups. Sustained release formulations, for example tablets 30 containing an enteric coating, are also envisaged.

For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthedc, preservatives and buffering agents are also dissolved in 5 the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. 10 Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.

Preferred parenteral formulations include aqueous formulations using sterile water or normal saline, at a pH of around 7.4 or greater, in particular, containing penciclovir sodium salt hydrate.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

A suitable dosage unit might contain from 50mg to lg of active ingredient, for example 100 to 500mg. Such doses may be administered 1 to 4 times a day or more usually 2 or 3 times a day. The effective dose of compound will, in general, be 20 in the range of from 0.2 to 40mg per kilogram of body weight per day or, more usually, 10 to 20 mg/kg per day. in the case of famciclovir, the dosage unit would be 125 mg, 250 mg, 500 mg or 750 mg, preferably 125 mg or 250 mg.

For prevention of establishment of competent latency, the treatment is preferably carried out as soon as possible after contact with the virus, preferably 25 within 18 hours, although up to four days is acceptable. The treatment period is usually 3 to 14 days, more usually 5 to 10 days, often 7 days.

For treatment of established recurrent disease, the treatment period is up to 5 years, for example, up to 1, 2, 3, 4, and 5 years.

The present invention also provides the use of a compound of formula (A) or 30 a bioprecursor, or a pharmaceutical^ acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing, in the manufacture of a medicament for use in the reduction or prevention of herpes virus infection becoming latent and subsequently reactivating in mammals, including humans, wherein administration of the medicament commences more than 18 hours post-infection. Such treatment may be carried out in O C the manner as hereinbefore described.

Pharmaceutical compositions for use in the treatment of latent infection of herpesviruses, which comprise an effective amount of a comgound_of formula (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosplj WO 96/18396 PCT/EP95/04692 29<7* ;derivative of either of the foregoing, and apharmaceutically acceptable earner, may' be prepared in the manner as hereinafter described. ;The compound of formula (A) and its prodrugs show a synergistic antiviral effect in conjunction with interferons; and treatment using combination products 5 comprising these two components for sequential or concomitant administration, by the same or different routes, are therefore within the ambit of the present invention. Such products are described in EP-A-271270 (Beecham Group p.l.c.). ;The following results from animal studies illustrate the invention. ;EXPERIMENTS IN MICE INFECTED WITH HSV-1 VIRUS ;A cutaneous infection was established by inoculation of the ear pinnae of mice with HSV-1 (SCI6) and the effects of oral famciclovir on the latent virus 15 infection was investigated. ;BALB/c female mice (Bantin and Kingman, Kingston, Hull, UK) were purchased at 3 to 4 weeks old and inoculated one week later. Virus suspension (lOul) containing 5 x 10^ p.f.u. were inoculated into the skin of the left ear pinna. Skin thickness was measured daily in individual mice by means of an Engineers' 20 micrometre screw gauge, (ref. Nash etal, 1980, J. Gen. Virol. 48, 351-357). These mice were kept for 3 (Experiment 1) or 4 (Experiment 2) months and then killled. The trigeminal ganglia and cervical dorsal root ganglia were removed and co-cultivated. Those cultures showing virus replication were recorded as positive. ;25 Experiment 1 ;In a first experiment, mice were treated within 18h and treatment ceased on day 10 post infection. ;Of the 24 untreated control mice, 12 showed latent infection in the trigeminal ganglia (TG) and 20 showed latent infection in the cervical dorsal route ganglia 30 (DRG). All 24 control mice showed either TG or DRG latency. None of the FCV treated mice showed any latency. ;Experiment 2 ;. In a second experiment, antiviral treatment was initiated on days 1, 2, 3, 4 or 5 35 post-infection (p.i.) and and ceased on day 10 p.i.. The compounds were administered ad libitum in the drinking water, at 1 mg/ml (approximately 100 mg/kg/day). n E 01= 1 V E O ;Inti'lK.".. i -.1 OIT ;1 7 1908 ;of New Zealand ;WO 96/18396 ;-6- ;PCT/EP95/04692 ;The results are as shown in the following table: ;(Note: The groups 1 and 2 received the same treatment regimens but the results were assayed separately.) ;Latency ;Latency ;Latency Total ;Acute Total ;(Group 1) ;(Group 2) ;% Mice with ;% Mice with ;virus -i-ve virus +ve ;Antiviral ;TG ;DRG ;TG ;DRG ;ganglia on day ganglia on day ;Therapy ;+ve/8 ;+ve/8 ;+ve/8 ;+ve/8 ;120 (n=16) ;8 (n=8) ;(days) ;Lt ;Rt ;Lt ;Rt ;Lt ;Rt ;Lt ;Rt ;L/RTG+DRG ;L/RTG+DRG ;None ;8 ;4 ;8 ;5 ;8 ;6 ;8 ;2 ;100 ;100 ;5-10 ;4 ;0 ;4 ;0 ;2 ;0 ;2 ;0 ;38 ;100 ;4-10 ;2 ;0 ;2 ;0 ;0 ;0 ;0 ;0 ;13 ;100 ;3-10 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;2-10 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;1-10 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;0 ;Four months later, latent virus could be reactivated in ganglia explants (ipsilateral and contralateral trigeminal and dorsal root) from all of 16 control mice. Latent virus was not reactivated from the ganglia of FCV-treated mice, except ipsilateral ganglia, and only when the start of therapy was delayed until days 4 p.i. ;10 (2/16) or 5 p.i (6/16). ;Similar results were obtained when compounds were administered twice daily by gavage at 50 mg/kg per dose. ;WO 96/18396 ;-7- ;PCT/EP95/04692 ;Experiment 3 ;Mice were immunosupressed with Cyclosporin A (CyA) from day -2 to day =10 (day 0 being the day of infection). Groups of mice were untreated (control), or treated with famciclovir orally at 50mg/kg twice daily from 22h after infection to 5.5 5 or 10.5 days. The ganglia were examined for reactivation of infectious virus 1 or 4 months later and the results are shown in the Table below. ;LTG RTG LDR RDR ;(n=6) (n=6) (n=6) (n=6) Control 6 4 6 3 FCV 0 0 0 0 ;TG = trigeminal DRG = dorsal root ganglia L/R = left/right ;10 ;EXPERIMENTS IN MICE INFECTED WITH HSV-2 VIRUS ;A cutaneous infection was established by inoculation of the ear pinnae of 15 mice with HSV-2 (Bry) and the effects of oral famciclovir on the latent virus infection was investigated. Treatment was 50 mg/kg twice daily for 5 days starting 22h post-infection. ;The table shows the number of mice/group with positive latent infection in the trigeminal or cervical dorsal root ganglia. ;20 ;No. of mice with +ve ganglia /number of mice tested ;Group Left T/G Right T/G Left CDR Right CDR ;Control 10/10 10/10 10/10 6/10 famciclovir 0/10 0/10 0/10 0/10 ;% mice yielding at least one +ve ganglion ;100 0 ;25 T/G = trigeminal CRG = Cervical dorsal root ganglia ;- 8 - ;* p ; ^

Claims (5)

CLAIMS:

1. The use of a compound of formula (A): O (CH2)2 hoch2-ch-ch2-oh (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing; in the manufacture of a medicament for use in the reduction or prevention of herpes virus infection becoming latent and subsequently reactivating in mammals, including humans, wherein administration of the medicament commences more than 18 hours post-infection.

2. A use according to claim 1 wherein the infection is herpes simplex type 1 infection.

3. A use according to claim 1 wherein the infection is herpes simplex type 2 infection.

4. A use according to claim 1, 2 or 3 wherein the Compound is famciclovir.

5. A use according to claim 4 wherein famciclovir is administered at a dose of 125 mg, 250 mg, 500 mg, 750 mg, or lg, once, twice or three times a day. END